Download PDF
Semin Liver Dis 2013; 33(02): 130-137
DOI: 10.1055/s-0033-1345713
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

New Therapeutic Targets and Drugs for the Treatment of Chronic Hepatitis B

Simon P. Fletcher
1   Department of Biology, Gilead Sciences, Foster City, California
,
William E. Delaney IV
1   Department of Biology, Gilead Sciences, Foster City, California
› Author Affiliations
Further Information

Publication History

Publication Date:
08 June 2013 (online)

    Permissions and Reprints

Abstract

Chronic hepatitis B virus (CHB) is managed effectively with either nucleoside/nucleotide-based or interferon-based therapies. However, most patients receiving these therapies do not establish long-term, durable control of infection after treatment withdrawal. In particular, rates of hepatitis B surface-antigen loss and seroconversion to antisurface-antigen antibody are very low. Thus, novel therapies and treatment modalities are necessary to achieve either elimination of the virus from the liver or durable immune control of hepatitis B virus (HBV) infection in the absence of chronic therapy (“functional cure”). Here the authors review new targets and approaches for treating CHB. These approaches can be divided into two broad categories—those targeting the virus or host factors required by the virus and those targeting the innate or adaptive immune systems. Unfortunately, although a variety of promising strategies have been identified and several new approaches have achieved preclinical validation, relatively few novel drug candidates are in active clinical studies to treat CHB. Thus, functional cure of CHB infection remains an important therapeutic challenge.

Keywords

hepatitis B virus (HBV) - antiviral therapy - immunotherapy - chronic hepatitis B - treatment
 

  • References

  • 1 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11 (2) 97-107
    CrossrefPubMedGoogle Scholar
  • 2 Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8 (5) 275-284
    PubMedGoogle Scholar
  • 3 Papatheodoridis G , et al; European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57 (1) 167-185
    PubMedGoogle Scholar
  • 4 Marcellin P, Gane E, Buti M , et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381 (9865) 468-475
    CrossrefPubMedGoogle Scholar
  • 5 Buster EH, Flink HJ, Cakaloglu Y , et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135 (2) 459-467
    CrossrefPubMedGoogle Scholar
  • 6 Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64 (1) 51-68
    CrossrefPubMedGoogle Scholar
  • 7 Seeger C, Zoulim F, Mason WS. Hepadnaviruses. In: Knipe DM, Howley PM, , eds. Fields Virology (Vol. 2). Philadelphia, PA: Lippincott Williams & Wilkins; 2007: 2977-3030
    Google Scholar
  • 8 Werle-Lapostolle B, Bowden S, Locarnini S , et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126 (7) 1750-1758
    CrossrefPubMedGoogle Scholar
  • 9 Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005; 79 (3) 1613-1622
    CrossrefPubMedGoogle Scholar
  • 10 Petersen J, Dandri M, Mier W , et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26 (3) 335-341
    CrossrefPubMedGoogle Scholar
  • 11 Volz T, Allweiss L , M Barek MB, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2012;
    PubMedGoogle Scholar
  • 12 Yan H, Zhong G, Xu G , et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human. hepatitis B and D virus . eLife 2012;1:e00049
    PubMedGoogle Scholar
  • 13 Haefeli WE, Blank A, Mikus G, Mier W, Alexandrov A, Urban S. Successful first administration of Myrcludex B, a first-in-class hepatitis B and D virus entry inhibitor, in humans. Hepatology 2012; 56: 372A
    PubMedGoogle Scholar
  • 14 Cai D, Mills C, Yu W , et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 2012; 56 (8) 4277-4288
    CrossrefPubMedGoogle Scholar
  • 15 Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 2010; 18 (5) 947-954
    CrossrefPubMedGoogle Scholar
  • 16 Händel EM, Gellhaus K, Khan K , et al. Versatile and efficient genome editing in human cells by combining zinc-finger nucleases with adeno-associated viral vectors. Hum Gene Ther 2012; 23 (3) 321-329
    CrossrefPubMedGoogle Scholar
  • 17 Zimmerman KA, Fischer KP, Joyce MA, Tyrrell DL. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol 2008; 82 (16) 8013-8021
    CrossrefPubMedGoogle Scholar
  • 18 Zhao X, Zhao Z, Guo J , et al. Creation of a six-fingered artificial transcription factor that represses the hepatitis B virus HBx gene integrated into a human hepatocellular carcinoma cell line. J Biomol Screen 2013; 18 (4) 378-387
    CrossrefPubMedGoogle Scholar
  • 19 Belloni L, Allweiss L, Guerrieri F , et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012; 122 (2) 529-537
    CrossrefPubMedGoogle Scholar
  • 20 Nash KL, Alexander GJ, Lever AM. Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes. J Viral Hepat 2005; 12 (4) 346-356
    CrossrefPubMedGoogle Scholar
  • 21 Welch PJ, Tritz R, Yei S, Barber J, Yu M. Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther 1997; 4 (7) 736-743
    CrossrefPubMedGoogle Scholar
  • 22 zu Putlitz J, Wieland S, Blum HE, Wands JR. Antisense RNA complementary to hepatitis B virus specifically inhibits viral replication. Gastroenterology 1998; 115 (3) 702-713
    CrossrefPubMedGoogle Scholar
  • 23 McCaffrey AP, Nakai H, Pandey K , et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21 (6) 639-644
    CrossrefPubMedGoogle Scholar
  • 24 Morrissey DV, Lockridge JA, Shaw L , et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23 (8) 1002-1007
    CrossrefPubMedGoogle Scholar
  • 25 Klein C, Bock CT, Wedemeyer H , et al. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 2003; 125 (1) 9-18
    CrossrefPubMedGoogle Scholar
  • 26 Keaney J, Campbell M, Humphries P. From RNA interference technology to effective therapy: how far have we come and how far to go?. Ther Deliv 2011; 2 (11) 1395-1406
    CrossrefPubMedGoogle Scholar
  • 27 Deres K, Schröder CH, Paessens A , et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003; 299 (5608) 893-896
    CrossrefPubMedGoogle Scholar
  • 28 Wang XY, Wei ZM, Wu GY , et al. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir Ther 2012; 17 (5) 793-803
    CrossrefPubMedGoogle Scholar
  • 29 Delaney IV WE, Edwards R, Colledge D , et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother 2002; 46 (9) 3057-3060
    CrossrefPubMedGoogle Scholar
  • 30 Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res 2007; 76 (2) 168-177
    CrossrefPubMedGoogle Scholar
  • 31 Wang P, Naduthambi D, Mosley RT , et al. Phenylpropenamide derivatives: anti-hepatitis B virus activity of the Z isomer, SAR and the search for novel analogs. Bioorg Med Chem Lett 2011; 21 (15) 4642-4647
    CrossrefPubMedGoogle Scholar
  • 32 Billioud G, Pichoud C, Puerstinger G, Neyts J, Zoulim F. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Res 2011; 92 (2) 271-276
    CrossrefPubMedGoogle Scholar
  • 33 Katen SP, Chirapu SR, Finn MG, Zlotnick A. Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem Biol 2010; 5 (12) 1125-1136
    CrossrefPubMedGoogle Scholar
  • 34 Stray SJ, Zlotnick A. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J Mol Recognit 2006; 19 (6) 542-548
    CrossrefPubMedGoogle Scholar
  • 35 Weber O, Schlemmer KH, Hartmann E , et al. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res 2002; 54 (2) 69-78
    CrossrefPubMedGoogle Scholar
  • 36 Brezillon N, Brunelle MN, Massinet H , et al. Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS ONE 2011; 6 (12) e25096
    CrossrefPubMedGoogle Scholar
  • 37 Xu Y, Hu Y, Shi B , et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol 2009; 46 (13) 2640-2646
    CrossrefPubMedGoogle Scholar
  • 38 Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS ONE 2011; 6 (1) e15324
    CrossrefPubMedGoogle Scholar
  • 39 Mahtab MA, Bazinet M, Vaillant A. REP 9AC': A second generation HBsAg release inhibitor with improved tolerability. Hepatology 2012; 56: 401A-402A
    PubMedGoogle Scholar
  • 40 Patient R, Hourioux C, Roingeard P. Morphogenesis of hepatitis B virus and its subviral envelope particles. Cell Microbiol 2009; 11 (11) 1561-1570
    CrossrefPubMedGoogle Scholar
  • 41 Block TM, Lu X, Platt FM , et al. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A 1994; 91 (6) 2235-2239
    CrossrefPubMedGoogle Scholar
  • 42 Block TM, Lu X, Mehta AS , et al. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 1998; 4 (5) 610-614
    CrossrefPubMedGoogle Scholar
  • 43 Dougherty AM, Guo H, Westby G , et al. A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob Agents Chemother 2007; 51 (12) 4427-4437
    CrossrefPubMedGoogle Scholar
  • 44 Yu W, Goddard C, Clearfield E , et al. Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J Med Chem 2011; 54 (16) 5660-5670
    CrossrefPubMedGoogle Scholar
  • 45 Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61 (12) 1754-1764
    CrossrefPubMedGoogle Scholar
  • 46 Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 1993; 104 (6) 1818-1821
    PubMedGoogle Scholar
  • 47 Lau GK, Suri D, Liang R , et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002; 122 (3) 614-624
    CrossrefPubMedGoogle Scholar
  • 48 Penna A, Laccabue D, Libri I , et al. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. J Hepatol 2012; 56 (6) 1239-1246
    CrossrefPubMedGoogle Scholar
  • 49 Micco L, Peppa D, Loggi E , et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 2013; 58 (2) 225-233
    CrossrefPubMedGoogle Scholar
  • 50 Byrnes-Blake KA, Pederson S, Klucher KM , et al. Pharmacokinetics and pharmacodynamics of pegylated interferon lambda-1 in cynomolgus monkeys. J Interferon Cytokine Res 2012; 32 (5) 198-206
    CrossrefPubMedGoogle Scholar
  • 51 Witte K, Gruetz G, Volk HD , et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009; 10 (8) 702-714
    CrossrefPubMedGoogle Scholar
  • 52 Chan H , et al. Peginterferon lambda, a new potential therapeutic option for the treatment of chronic hepatitis B: a phase 2B comparison with peginterferon alfa in patients with HBeAg- positive disease. Hepatology 2012; 56: 1525A-1526A
    PubMedGoogle Scholar
  • 53 Ji C, Sastry KS, Tiefenthaler G , et al. Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies. Hepatology 2012; 56 (6) 2027-2038
    CrossrefPubMedGoogle Scholar
  • 54 Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 2009; 324 (5934) 1569-1572
    CrossrefPubMedGoogle Scholar
  • 55 Fröhlich A, Kisielow J, Schmitz I , et al. IL-21R on T-cells is critical for sustained functionality and control of chronic viral infection. Science 2009; 324 (5934) 1576-1580
    CrossrefPubMedGoogle Scholar
  • 56 Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009; 324 (5934) 1572-1576
    CrossrefPubMedGoogle Scholar
  • 57 Pellegrini M, Calzascia T, Toe JG , et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011; 144 (4) 601-613
    CrossrefPubMedGoogle Scholar
  • 58 Nanjappa SG, Kim EH, Suresh M. Immunotherapeutic effects of IL-7 during a chronic viral infection in mice. Blood 2011; 117 (19) 5123-5132
    CrossrefPubMedGoogle Scholar
  • 59 Publicover J, Goodsell A, Nishimura S , et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest 2011; 121 (3) 1154-1162
    CrossrefPubMedGoogle Scholar
  • 60 Kennedy PT, Sandalova E, Jo J , et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 2012; 143 (3) 637-645
    CrossrefPubMedGoogle Scholar
  • 61 Hashmi MH, Van Veldhuizen PJ. Interleukin-21: updated review of phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther 2010; 10 (5) 807-817
    CrossrefPubMedGoogle Scholar
  • 62 Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11 (5) 330-342
    CrossrefPubMedGoogle Scholar
  • 63 Zhang X, Kraft A, Broering R, Schlaak JF, Dittmer U, Lu M. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opin Drug Discov 2012; 7 (7) 597-611
    CrossrefPubMedGoogle Scholar
  • 64 Menne S , et al. Anti-viral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection. J Hepatol 2011; 54: S441
    PubMedGoogle Scholar
  • 65 Lanford RE, Guerra B, Chavez D , et al. GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanze. Gastroenterology 2013; Feb 13 [Epub ahead of print]
    PubMedGoogle Scholar
  • 66 Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5 (3) 215-229
    CrossrefPubMedGoogle Scholar
  • 67 Boni C, Penna A, Bertoletti A , et al. Transient restoration of anti-viral T-cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39 (4) 595-605
    CrossrefPubMedGoogle Scholar
  • 68 Boni C, Laccabue D, Lampertico P , et al. Restored function of HBV-specific T-cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143 (4) 963-973
    CrossrefPubMedGoogle Scholar
  • 69 Xu DZ, Zhao K, Guo LM , et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 2008; 3 (7) e2565
    CrossrefPubMedGoogle Scholar
  • 70 Bertoletti A, Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol 2009; 3 (5) 561-569
    CrossrefPubMedGoogle Scholar
  • 71 Kemmler CB , et al. Recombinant yeast therapeutic vaccines expressing hepatitis B virus (HBV) X, S, and core antigens generate antigen specific T-cell responses in immune samples from healthy and chronic HBV donors. Hepatology 2012; 56: 373A-374A
    CrossrefPubMedGoogle Scholar
  • 72 Guo Z , et al. Recombinant yeast therapeutic vaccines expressing hepatitis B virus (HBV) X, S and core antigens generate antigen specific T-cell responses and tumor protection in mice. Hepatology 2012; 56: 375A-376A
    PubMedGoogle Scholar
  • 73 Crawford A, Wherry EJ. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr Opin Immunol 2009; 21 (2) 179-186
    CrossrefPubMedGoogle Scholar
  • 74 Fisicaro P, Valdatta C, Massari M , et al. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T-cells against HBV, but not HCV. Gastroenterology 2012; 143 (6) 1576-1585 , e4
    CrossrefPubMedGoogle Scholar
  • 75 Fisicaro P, Valdatta C, Massari M , et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010; 138 (2) 682-693 , e1–e4
    CrossrefPubMedGoogle Scholar
  • 76 Topalian SL, Hodi FS, Brahmer JR , et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366 (26) 2443-2454
    CrossrefPubMedGoogle Scholar
  • 77 Brahmer JR, Tykodi SS, Chow LQ , et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366 (26) 2455-2465
    CrossrefPubMedGoogle Scholar
  • 78 Hodi FS, O'Day SJ, McDermott DF , et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (8) 711-723
    CrossrefPubMedGoogle Scholar
  • 79 Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006; 12 (11) 1301-1309
    CrossrefPubMedGoogle Scholar
  • 80 Ejrnaes M, Filippi CM, Martinic MM , et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006; 203 (11) 2461-2472
    CrossrefPubMedGoogle Scholar
  • 81 Tinoco R, Alcalde V, Yang Y, Sauer K, Zuniga EI. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T-cell deletion and viral persistence in vivo. Immunity 2009; 31 (1) 145-157
    CrossrefPubMedGoogle Scholar
  • 82 Peppa D, Micco L, Javaid A , et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 2010; 6 (12) e1001227
    CrossrefPubMedGoogle Scholar
  • 83 Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012; 11 (10) 790-811
    CrossrefPubMedGoogle Scholar
  • 84 Manigold T, Racanelli V. T-cell regulation by CD4 regulatory T-cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis 2007; 7 (12) 804-813
    CrossrefPubMedGoogle Scholar
  • 85 Rech AJ, Mick R, Martin S , et al. CD25 blockade depletes and selectively reprograms regulatory T-cells in concert with immunotherapy in cancer patients. Sci Transl Med 2012; 4 (134) 34ra62
    PubMedGoogle Scholar
  • 86 Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ. Toll-like receptors on regulatory T-cells: expanding immune regulation. Trends Immunol 2006; 27 (8) 387-393
    CrossrefPubMedGoogle Scholar
  • 87 Otano I, Suarez L, Dotor J , et al. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. Hepatology 2012; 56 (2) 474-483
    CrossrefPubMedGoogle Scholar